<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1997-06-12" id="root" itemid="657589" xml:lang="en">
<title>USA: RESEARCH ALERT - Barr Laboratories cut.</title>
<headline>RESEARCH ALERT - Barr Laboratories cut.</headline>
<dateline>NEW YORK 1997-06-12</dateline>
<text>
<p>Gruntal &amp; Co said it downgraded Barr Laboratories Inc to hold from buy.</p>
<p>-- said stock has surpassed its one-year price target of $33.</p>
<p>-- also cited flat-to-down near-term earning outlook, ample price/earnings valuation, and recent setback with Premarin, a drug for menopause and osteoperosis. The U.S. Food and Drug Administration said Premarin is not generically equivalent to the brand drug.</p>
<p>-- said still "enthusiastic" about long-term outlook for Barr.</p>
<p>-- Barr was up 9/16 to 36.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<dc element="dc.date.created" value="1997-06-12" />
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1997-06-12" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location" value="NEW YORK" />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>